• en
ON NOW

Japan Approves Rheumatoid Drug Baricitinib for Covid-19 Patients

Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone. Eli Lilly & Co’s

Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.

Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.

Follow us on:

ON NOW